Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lisata Therapeutics ( (LSTA) ) has shared an update.
On May 3, 2026, Lisata Therapeutics, Inc. and Kuva Labs Inc., together with Kuva Acquisition Corp., amended their March 6, 2026 merger agreement to extend the deadline for commencing Kuva’s tender offer for all outstanding Lisata common shares from April 13, 2026 to May 29, 2026, or a later agreed date. As part of the amendment, Kuva Labs agreed to cover certain Lisata expenses up to an aggregate $1.1 million until the offer begins, providing interim financial support during the delayed launch of the transaction.
In exchange, Lisata agreed that from May 3, 2026 until May 29, 2026 it will not pursue claims against Kuva Labs, Kuva Acquisition Corp. or their affiliates related to the merger agreement, and upon commencement of the offer and full payment of amounts due, it will irrevocably waive claims tied to the missed April 13, 2026 tender offer start date. These non-assertion and waiver commitments can be terminated by Lisata if Kuva fails to make required payments or materially breaches the amendment, underscoring ongoing conditionality and risk management around the delayed deal execution.
The most recent analyst rating on (LSTA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.
Spark’s Take on LSTA Stock
According to Spark, TipRanks’ AI Analyst, LSTA is a Neutral.
The score is held down primarily by weak financial performance (limited/declining revenue, ongoing losses, and persistent cash burn). Technicals add near-term pressure with the stock below key short-term moving averages, though oversold indicators provide some counterbalance. Corporate events provide upside via the pending takeout structure, but delays and other execution risks prevent a higher score.
To see Spark’s full report on LSTA stock, click here.
More about Lisata Therapeutics
Lisata Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics, operating in a sector where strategic transactions and partnerships are common tools to advance pipelines and create shareholder value. The company’s capital markets activity and merger-related developments are closely watched by investors assessing its long-term prospects.
Average Trading Volume: 80,183
Technical Sentiment Signal: Sell
Current Market Cap: $28.5M
Find detailed analytics on LSTA stock on TipRanks’ Stock Analysis page.